Investing.comDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 06:04:39·⟳ 抓取 06:05:05 +26s·⚡ 决策 10-19 06:08:22 +3m17s·8.8 天前
Veradermics预告下周一公布VDPHL01脱发药III期Study 304结果，当前无数据、纯二元事件
这是临床数据公布的'会前预告'，不含Study 304任何疗效/安全性结果，方向完全取决于周一8:00 ET的未知二元数据；在数据前做多或做空均为押硬币。当前为美东周日、美股闭市，下一可成交窗口(周一盘前/开盘)将在电话会(8:00 ET，盘前)之后，届时跳空已反映数据，本预告不提供任何可执行的提前edge。MANE近5日-16.9%、20日已实现波动率高，盘前二元跳空风险使无条件入场风险收益极差。
📄 原文Investing.com↗ 原文
Veradermics to present phase 3 hair loss trial results Monday
Buy these 2 stocks amid AI financing concerns: Analyst NEW HAVEN, Conn. - Veradermics, Incorporated (NYSE:MANE) will ho…
不做 Veradermics, Incorporated（MANE.US）
本信号仅为周一盘前III期Study 304数据公布的日程预告，无任何疗效/安全性数据、方向未知；美东周日闭市，下一可成交时点已在电话会(8:00 ET盘前)之后，跳空即反映数据，会前无领先edge。二元临床事件+近5日-16.9%高波动，会前做多或做空均为方向押注、风险收益差；等待周一数据落地后依据实际结果(终点是否达成、疗效幅度、米诺地尔系统性安全性)再行研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Veradermics预告周一盘前公布III期脱发药Study 304结果，但新闻无数据、方向未知，且美股周末闭市、开盘即在数据跳空之后，会前无可交易edge，故AVOID；应等周一数据落地后按实际结果另行研判。
🔎 新鲜度:最早出现 2026-10-18 · 扩散 low · price-in 风险 medium ↗
消息传播链
- Investing.com(据公司新闻稿)预告Veradermics将于周一8:00 a.m. ET电话会公布III期Study 304 Part A结果；为二手转述公司press release，正文无任何数据。
关键理由
- 本信号仅是数据公布日程、无Study 304结果，缺乏方向性新增事实，不构成可交易催化。
- 唯一可交易标的MANE将在周一盘前8:00 ET率先吸收二元数据，当前(周日)无成交窗口、无提前布局edge。
主要风险
- 周一盘前数据若超预期或不及预期，MANE可能大幅跳空，方向与幅度均不可在本信号下预判。
- 米诺地尔口服制剂的系统性安全性(低血压、体液潴留、心率等)若出现信号，可能显著压低开后估值。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
近5日-16.9%、近10日大幅震荡(10-08 +14%后连续回落)，会前存在明显获利了结/担忧情绪；未检索到针对304的具体做空报告或已确认利空，但高波动与未决二元数据不支持会前无条件做多。
检索:Veradermics MANE Study 304 concerns short report safety minoxidil October 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-04-27 · 影响 weakens
Study 302已阳性、若304重复阳性将强化首个男女双适应症口服非激素脱发药叙事，存在向上跳空风险；会前做空同样无edge且逼空/跳空风险高。
检索:Veradermics VDPHL01 Study 304 positive expectations analyst hair loss oral minoxidil 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失进一步支持在数据前AVOID，不设方向性入场与止盈止损；待数据落地后再以真实结果和同公司Study 302(2026-04-27)反应做对齐复盘。
方向:无可用于本次决策的对齐先例：本信号本身无数据，价格反应完全由尚未公布的Study 304决定，历史其他临床数据日的涨跌对'会前是否进场'这一判断不提供方向。
涨幅量级:不足，未用任何先例校准tp/sl。
形态:无法在会前判明见光死或正向跳空；MANE属高波动小盘临床股，数据日跳空幅度通常大但方向依赖数据。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 14 ms
{"result": "search_processed_events:agent query=`veradermics mane minoxidil phase 3 topline data october 2026 | veradermics vdphl01 phase 3 study 304 hair loss results monday investor call`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续 - web_search 成功 doubao_search · 1,369 ms
豆包搜索结果（原始查询:Veradermics MANE VDPHL01 Phase 3 Study 304 results November 2026 minoxidil hair loss；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 1,899 ms
{
原文全文
展开原文 · 1,935 字
Buy these 2 stocks amid AI financing concerns: Analyst
NEW HAVEN, Conn. - Veradermics, Incorporated (NYSE:MANE) will host an investor call on Monday at 8:00 a.m. ET to review results from Part A of its Phase 3 clinical trial evaluating VDPHL01 for pattern hair loss treatment, according to a press release statement.
The randomized, double-blind, placebo-controlled trial, designated Study 304, enrolled over 500 males with mild-to-moderate pattern hair loss. The study evaluated VDPHL01, an extended-release oral minoxidil formulation, at doses of 8.5 mg once and twice daily.
VDPHL01 is an investigational oral non-hormonal drug currently in Phase 3 development for pattern hair loss in both women and men. The formulation uses extended-release technology designed to deliver steady release of minoxidil.
The company’s registration-directed clinical development program comprises three multicenter trials that enrolled more than 1,600 adult men and women with mild-to-moderate pattern hair loss. Each trial follows a 52-week design with a six-month placebo-controlled period followed by a six-month extension.
The three trials include Study 302, a Phase 2/3 trial in 519 men; Study 304, the Phase 3 trial in 536 men; and Study 306, a Phase 2/3 trial of VDPHL01 4.5 mg in 556 women. Study 306 is described as the first registration-directed trial of an oral therapy specifically for female pattern hair loss in the U.S.
The trials are designed to support potential FDA approval of VDPHL01 in both male and female pattern hair loss. If approved, the company states VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both patient populations.
The event will be available on the Events page in the Investors section of the company’s website, with a replay available following the call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW HAVEN, Conn. - Veradermics, Incorporated (NYSE:MANE) will host an investor call on Monday at 8:00 a.m. ET to review results from Part A of its Phase 3 clinical trial evaluating VDPHL01 for pattern hair loss treatment, according to a press release statement.
The randomized, double-blind, placebo-controlled trial, designated Study 304, enrolled over 500 males with mild-to-moderate pattern hair loss. The study evaluated VDPHL01, an extended-release oral minoxidil formulation, at doses of 8.5 mg once and twice daily.
VDPHL01 is an investigational oral non-hormonal drug currently in Phase 3 development for pattern hair loss in both women and men. The formulation uses extended-release technology designed to deliver steady release of minoxidil.
The company’s registration-directed clinical development program comprises three multicenter trials that enrolled more than 1,600 adult men and women with mild-to-moderate pattern hair loss. Each trial follows a 52-week design with a six-month placebo-controlled period followed by a six-month extension.
The three trials include Study 302, a Phase 2/3 trial in 519 men; Study 304, the Phase 3 trial in 536 men; and Study 306, a Phase 2/3 trial of VDPHL01 4.5 mg in 556 women. Study 306 is described as the first registration-directed trial of an oral therapy specifically for female pattern hair loss in the U.S.
The trials are designed to support potential FDA approval of VDPHL01 in both male and female pattern hair loss. If approved, the company states VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both patient populations.
The event will be available on the Events page in the Investors section of the company’s website, with a replay available following the call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
220990aa14· 2026-10-19 06:08 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前